Shuttle Pharmaceuticals Files 2024 Proxy Statement

TL;DR

Shuttle Pharma (SHPH) filed its proxy statement for the June 20th annual meeting - vote your shares!

AI Summary

Shuttle Pharmaceuticals Holdings, Inc. filed its definitive proxy statement for its 2024 Annual Meeting of Stockholders on June 20, 2024. The filing, a DEF 14A, outlines the agenda and proposals to be voted on by shareholders. Key items likely include the election of directors and ratification of independent auditors, as is typical for such annual meetings.

Why It Matters

This filing provides shareholders with crucial information to make informed voting decisions on company leadership and governance at the upcoming annual meeting.

Risk Assessment

Risk Level: medium — Proxy statements are routine filings, but the specific proposals and any contested matters could introduce risk.

Key Players & Entities

• Shuttle Pharmaceuticals Holdings, Inc. (company) — Registrant
• 2024 Annual Meeting of Stockholders (event) — Meeting subject
• June 20, 2024 (date) — Filing date and meeting date

FAQ

Filing Documents

• formdef14a.htm (DEF 14A) — 440KB
• formdef14a_001.jpg (GRAPHIC) — 1KB
• formdef14a_002.jpg (GRAPHIC) — 2KB
• formdef14a_003.jpg (GRAPHIC) — 1KB
• formdef14a_004.jpg (GRAPHIC) — 1KB
• formdef14a_005.jpg (GRAPHIC) — 1KB
• formdef14a_006.jpg (GRAPHIC) — 1KB
• formdef14a_007.jpg (GRAPHIC) — 1KB
• formdef14a_008.jpg (GRAPHIC) — 1KB
• formdef14a_009.jpg (GRAPHIC) — 5KB
• formdef14a_010.jpg (GRAPHIC) — 4KB
• formdef14a_011.jpg (GRAPHIC) — 2KB
• proxy_001.jpg (GRAPHIC) — 250KB
• proxy_002.jpg (GRAPHIC) — 159KB
• 0001493152-24-024491.txt ( ) — 1035KB

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 15

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 18 RELATED PARTY TRANSACTIONS 19 FREQUENTLY ASKED QUESTIONS 26 OTHER MATTERS 30 2 Proxy Summary About the Meeting DATE AND TIME July 31, 2024 at 12:00 P.M. EST MEETING You can attend the Annual Meeting virtually via the Internet by visiting www.virtualshareholdermeeting.com/SHPH2024. RECORD DATE June 14, 2024 STOCK EXCHANGE The common stock of the Company is listed on The Nasdaq Capital Market under the symbol “SHPH.” PROXY VOTING Internet Meeting Phone Mail Visit the web site listed on your proxy card Vote at the Annual Meeting online at www.virtualshareholdermeeting.com/SHPH2024 Call the telephone number on your proxy card Sign, date and return your proxy card in the enclosed envelope PROPOSAL 1: ELECTION OF DIRECTORS The Board of Directors recommends that you vote FOR each director nominee. These individuals bring a range of relevant experiences and overall diversity of perspectives that is essential to good governance and leadership of our Company. PROPOSAL 2: RATIFICATION OF INDEPENDENT PUBLIC ACCOUNTING FIRM The Board of Directors recommends that you vote FOR the ratification of the Company’s independent auditor, Forvis Mazars LLP. PROPOSAL 3: EXECUTIVE COMPENSATION The Board of Directors recommends that you vote FOR approval of the Company’s executive compensation plan, on an advisory basis. We believe the existing executive compensation structure for our named executive officers, as presented herein, is fair and in the best interest of the Company’s executives and stockholders alike. PROPOSAL NO. 4: AUTHORIZATION OF THE BOARD OF DIRECTORS TO AMEND THE COMPANY’S AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO EFFECT A REVERSE STOCK SPLIT OF ALL OF THE COMPANY’S ISSUED AND OUTSTANDING COMMON STOCK BY A RATIO IN THE RANGE OF 1-FOR-3 TO 1-FOR-8 (THE “REVERSE STOCK SPLIT”). The Board of D

: Gender Identity

Part I: Gender Identity Directors 1 5 - -

: Demographic Background

Part II: Demographic Background African American or Black - 1 - - Alaskan Native or Native American 1 - - - Asian - 1 - - Hispanic or Latinx - - - - Native Hawaiian or Pacific Islander - - - - White - 3 - - Two or More Races or Ethnicities - - - - LGBTQ+ - Did Not Disclose Demographics Background - nominees for Director Anatoly Dritschilo, M.D. Chief Executive Officer and Chairman Age: 80 Director since: December 2012 Committees: N/A Milton Brown, M.D., Ph.D., FNAI Chief Scientific Officer and Director Age: 58 Director since: December 2012 Committees: N/A Chris H. Senanayake, Ph.D. Independent Director Age: 66 Director since: January 2021 Committees: Audit Committee Member Steven Richards Independent Director Age: 55 Director since: May 2019 Committees: Chair of Audit Committee, Chair of Corporate Governance Committee and Compensation Committee Member Joshua Schafer Independent Director Age: 53 Director since: May 2019 Committees: Chair of Compensation Committee and Corporate Governance Committee Member Bette Jacobs, Ph.D. Independent Director Age: 73 Director since: October 2022 Committees: Audit Committee Member and Corporate Governance Committee Member Director Independence As of the date of this proxy statement, Steven Richards, Dr. Chris H. Senanayake, Joshua Schafer and Dr. Bette Jacobs are our independent directors. As a Nasdaq listed company, we believe that the foregoing directors satisfy the definition of “Independent Director” under Nasdaq Rule 5605(a)(2). In making this determination, our Board of Directors considered the relationships that each of these non-employee directors has with us and all other facts and circumstances our Board of Directors deemed relevant in determining their independence. As required under applicable Nasdaq rules, we anticipate that our independent directors will meet on a r

View Full Filing

View this DEF 14A filing on SEC EDGAR